Opinion

Video

Generalized Myasthenia Gravis Pipeline

Key Takeaways

  • Novel therapeutic agents for gMG target specific disease pathways, potentially improving efficacy and safety over traditional treatments.
  • Complement inhibitors and FcRn antagonists are among the promising emerging treatments for gMG.
SHOW MORE

Panelists discuss how emerging agents for generalized myasthenia gravis (gMG) show promise in addressing current treatment gaps, highlighting specific therapies they find particularly exciting for future management of the condition.

Related Videos
2 experts in this video
Michael Levy, MD, PhD, is featured in this series.
2 experts in this video
2 experts in this video
2 experts in this video
Michael Levy, MD, PhD, is featured in this series.
Michael Levy, MD, PhD, is featured in this series.
Michael Levy, MD, PhD, is featured in this series.
Related Content
© 2024 MJH Life Sciences

All rights reserved.